Clinical Trials
11 trialsNCT06322147 2024-03-20
Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer
Qilu Hospital of Shandong University
Unknown
NCT04189055 2023-06-12
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Phase 2 Unknown
NCT05278351 2023-03-31
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05074966 2021-10-12
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
ChineseAMS
Phase 3 Unknown
NCT03608046 2020-10-22
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT00182715 2013-09-17
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01190462 2013-08-12
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00482222 2013-01-23
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Phase 3 Unknown
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown